KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Current Assets: 2009-2025

Historic Current Assets for Rigel Pharmaceuticals (RIGL) over the last 16 years, with Sep 2025 value amounting to $214.9 million.

  • Rigel Pharmaceuticals' Current Assets rose 101.87% to $214.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $214.9 million, marking a year-over-year increase of 101.87%. This contributed to the annual value of $135.1 million for FY2024, which is 36.10% up from last year.
  • Rigel Pharmaceuticals' Current Assets amounted to $214.9 million in Q3 2025, which was up 22.54% from $175.4 million recorded in Q2 2025.
  • Rigel Pharmaceuticals' Current Assets' 5-year high stood at $214.9 million during Q3 2025, with a 5-year trough of $92.5 million in Q1 2024.
  • Over the past 3 years, Rigel Pharmaceuticals' median Current Assets value was $106.5 million (recorded in 2024), while the average stood at $124.3 million.
  • Its Current Assets has fluctuated over the past 5 years, first tumbled by 35.45% in 2022, then soared by 101.87% in 2025.
  • Rigel Pharmaceuticals' Current Assets (Quarterly) stood at $154.5 million in 2021, then declined by 24.97% to $115.9 million in 2022, then decreased by 14.35% to $99.3 million in 2023, then soared by 36.10% to $135.1 million in 2024, then skyrocketed by 101.87% to $214.9 million in 2025.
  • Its last three reported values are $214.9 million in Q3 2025, $175.4 million for Q2 2025, and $146.6 million during Q1 2025.